SCHEMBL1754740

SCHEMBL1754740

Cc1cc(-c2ccccc2)n[nH]c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.61
POLB P06746 2/20 0.53
RAB9A P51151 2/20 0.53
CYP1A2 P05177 1/20 0.52
TP53 P04637 1/20 0.51
CHEK1 O14757 1/20 0.50
RET P07949 1/20 0.50
PDGFRB P09619 1/20 0.50
PIM1 P11309 1/20 0.50
PDGFRA P16234 1/20 0.50
GSK3B P49841 1/20 0.50
RPS6KA3 P51812 1/20 0.50
LIMK1 P53667 1/20 0.50
CDK5 Q00535 1/20 0.50
TYRO3 Q06418 1/20 0.50
MAPK14 Q16539 1/20 0.50
LRRK2 Q5S007 1/20 0.50
AURKB Q96GD4 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
DYRK1B Q9Y463 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11396912 0.96 L3MBTL1 (0.58) L3MBTL1POLBRAB9ACYP1A2TP53
SCHEMBL11396914 0.86 JAK2 (0.47) L3MBTL1POLBRAB9ACYP1A2TP53
SCHEMBL1753098 0.82 ALPL (0.53) L3MBTL1POLBRAB9ATP53RET
SCHEMBL22130300 0.82 ALPL (0.53) L3MBTL1POLBRAB9ARETGSK3B
SCHEMBL17016671 0.82 MAPT (0.59) RAB9ARETMAPTATMMEN1
SCHEMBL1752841 0.82 ALPL (0.54) L3MBTL1POLBRAB9ARETGSK3B
SCHEMBL31759053 0.82 CA12 (0.56) L3MBTL1POLBCYP1A2PDGFRBKDM4E
SCHEMBL11628214 0.82 NOTUM (0.48) POLBPDGFRBADORA3ALDH1A1
SCHEMBL29295442 0.82 CA12 (0.56) L3MBTL1POLBCYP1A2PDGFRBKDM4E
SCHEMBL7264540 0.81 ALK (0.61) CYP1A2CHEK1RETPDGFRBPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008771-A1 PYRIDAZINE BASED SMALL MOLECULE INHIBITOR OF COGNITIVE IMPAIRMENT NORTHWESTERN UNIVERSITY 2026-01-08 US disclosed
EP-2063894-B1 FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES UNIV NORTHWESTERN (US) 2019-08-28 EP disclosed
EP-2063894-B1 FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES UNIV NORTHWESTERN (US) 2019-08-28 EP disclosed
US-9663493-B2 Pyridazine compounds, compositions and methods NORTHWESTERN UNIVERSITY (US) 2017-05-30 US disclosed
US-9527819-B2 Pyridazine compounds, compositions and methods NORTHWESTERN UNIVERSITY 2016-12-27 US disclosed
US-20160326139-A1 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS NORTHWESTERN UNIVERSITY (US) 2016-11-10 US disclosed
US-9408845-B2 Formulations containing pyridazine compounds NORTHWESTERN UNIVERSITY (US) 2016-08-09 US disclosed
US-20150175555-A1 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS NORTHWESTERN UNIVERSITY (US) 2015-06-25 US disclosed
EP-2592075-B1 PYRIDAZINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES UNIV NORTHWESTERN (US) 2015-04-29 EP disclosed
US-8933076-B2 Pyridazine compounds, compositions and methods CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-01-13 US disclosed
WO-2007130383-A2 COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES NORTHWESTERN UNIVERSITY (US) 2007-11-15 WO disclosed
WO-2007127475-A2 PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN NORTHWESTERN UNIVERSITY (US) 2007-11-08 WO disclosed
WO-2007127375-A2 FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES NORTHWESTERN UNIVERSITY (US) 2007-11-08 WO disclosed
WO-2007127448-A2 SALTS OF PYRIDAZINE COMPOUNDS NORTHWESTERN UNIVERSITY (US) 2007-11-08 WO disclosed
EP-1812408-A2 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS Northwestern University (US) 2007-08-01 EP disclosed
WO-2006050389-A2 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS NORTHWESTERN UNIVERSITY (US) 2006-05-11 WO disclosed
US-5883090-A Endothelin receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-03-16 US disclosed
US-4404203-A AND 6-PHENYL-4,5-DIHYDRO-3/2H/-PYRIDAZINONES WARNER-LAMBERT COMPANY (US) 1983-09-13 US disclosed
US-4397854-A INCREASE IN MYOCARDIAL CONTRACTILITY WARNER-LAMBERT COMPANY (US) 1983-08-09 US disclosed
US-4230705-A 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety AMERICAN CYANAMID COMPANY (US) 1980-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008771-A1 PYRIDAZINE BASED SMALL MOLECULE INHIBITOR OF COGNITIVE IMPAIRMENT PSEN1, PSEN2, CHRNA6 L3MBTL1 1746/4885POLB 3842/4885RAB9A 289/4885
US-20160326139-A1 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS PSEN1, PSEN2, APP L3MBTL1 4807/4885POLB 2949/4885RAB9A 4206/4885
US-20150175555-A1 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS PSEN1, PSEN2, APP L3MBTL1 4807/4885POLB 2949/4885RAB9A 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.